This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OCUP Ocuphire Pharma (OCUP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ocuphire Pharma Stock (NASDAQ:OCUP) 30 days 90 days 365 days Advanced Chart Get Ocuphire Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.17▼$1.4652-Week Range N/AVolume676,700 shsAverage Volume171,840 shsMarket Capitalization$30.33 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.Read More… Receive OCUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUP Stock News HeadlinesNight Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, ViatrisApril 10, 2025 | theglobeandmail.comShareholder group nominates slate of director candidates for Opus GeneticsFebruary 7, 2025 | markets.businessinsider.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)Opus Genetics sets April 30 for 2025 Annual MeetingJanuary 24, 2025 | msn.comOpus Genetics reinstated with a Buy at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comOpus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deSee More Headlines OCUP Stock Analysis - Frequently Asked Questions How were Ocuphire Pharma's earnings last quarter? Ocuphire Pharma, Inc. (NASDAQ:OCUP) released its quarterly earnings results on Friday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.01. The company earned $3.67 million during the quarter. Ocuphire Pharma had a negative net margin of 85.75% and a negative trailing twelve-month return on equity of 30.19%. What other stocks do shareholders of Ocuphire Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/11/2023Today5/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUP CIK1228627 Webwww.ocuphire.com Phone(248) 681-9815Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$18.00 Low Stock Price Target$10.00 Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,990,000.00 Net Margins-85.75% Pretax Margin-85.68% Return on Equity-30.19% Return on Assets-27.55% Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68 Sales & Book Value Annual Sales$16.45 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / BookN/AMiscellaneous Outstanding Shares25,924,000Free Float24,469,000Market Cap$30.33 million OptionableOptionable Beta0.20 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:OCUP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.